Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Mannosylated poly(acrylic acid)-coated mesoporous silica nanoparticles for anticancer therapy.

Author information

Affiliations

  • 1. College of Pharmacy and Institute of Drug Research and Development Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 34134, Republic of Korea.
      Authors
    • Lee H 1
    • Choi M 1
    • Kim HE 1
    • Jin M 1
    • Jeon WJ 1
    • Jung M 1
    • Yoo H 1
    • Won JH 1
    • Na YG 1
    • Lee JY 1
    • Cho CW 1
    (11 authors)
  • 2. Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, Republic of Korea.
      Authors
    • Seong H 2
    (1 author)
  • 3. Human Health Risk Assessment Center, Jeonbuk Branch, Korea Institute of Toxicology (KIT), Jeongeup, 53212, Republic of Korea; Center for Companion Animal New Drug Development, Jeonbuk Branch, Korea Institute of Toxicology (KIT), Jeongeup, 53212, Republic of Korea.
      Authors
    • Lee HK 3
    (1 author)

Journal of Controlled Release : Official Journal of the Controlled Release Society, 08 Jul 2022, 349:241-253
https://doi.org/10.1016/j.jconrel.2022.06.064 PMID: 35798094 

Abstract 

Although mesoporous silica nanoparticles (MSNs) are widely used as anticancer drug carriers, unmodified MSNs induce off-target effects and at high doses, there are adverse effects of hemolysis because of the interaction with the silanol group on the surface and cells. In this study, we developed doxorubicin (DOX)-loaded MSNs coated with mannose grafted poly (acrylic acid) copolymer (DOX@MSNs-man-g-PAA) to enhance the hemocompatibility and target efficacy to cancer cells. This uniform nanosized DOX@MSNs-man-g-PAA showed sustained and pH-dependent drug release with improved hemocompatibility over the bare MSNs. The uptake of the DOX@MSN-man-g-PAA in breast cancer cells was significantly improved by mannose receptor-mediated endocytosis, which showed significant increasing intracellular ROS and changes in mitochondrial membrane potential. This formulation exhibited superior tumor-suppressing activity in the MDA-MB-231 cells inoculated mice. Overall, the present study suggested the possibility of the copolymer-coated MSNs as drug carriers for cancer therapy.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.jconrel.2022.06.064

Citations & impact 

Impact metrics

4
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/131015267
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/131015267

Article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Ministry of Science, ICT and Future Planning (1)

National Research Council of Science and Technology

    National Research Foundation of Korea (1)